Chelation of bismuth by combining desferrioxamine and deferiprone in rats

Toxicology and Industrial Health

Volumn 24, Issue 4, 2008, Pages 235-240

  Tubafard, S ^a   Fatemi, Sj ^a  

^a SHAHID BAHONAR UNIVERSITY OF KERMAN   (Iran)

Author keywords

bismuth; bismuth chelators; bismuth rats; chelation; deferiprone; desferrioxamine; iron

Indexed keywords

BISMUTH; DEFERIPRONE; DEFEROXAMINE; IRON;

ABSORPTION; ANIMAL EXPERIMENT; ARTICLE; BISMUTH POISONING; BODY WEIGHT; CHELATION; CONTROLLED STUDY; INTOXICATION; KIDNEY DISEASE; LIVER DISEASE; MALE; NONHUMAN; RAT; SKIN MANIFESTATION;

ANIMALS; BISMUTH; BODY WEIGHT; CHELATION THERAPY; DEFEROXAMINE; DRUG THERAPY, COMBINATION; EATING; IRON; IRON CHELATING AGENTS; KIDNEY; MALE; PYRIDONES; RATS; RATS, WISTAR; SIDEROPHORES;

RATTUS;

EID: 57049167610     PISSN: 07482337     EISSN: None     Source Type: Journal    
DOI: 10.1177/0748233708095771     Document Type: Article

References (17)

1. Barman Balfour JA, Foster RH (1999) Deferiprone: a review of its clinical potential in iron overload in β-thalassemia major and other transfusion-dependant diseases. Drugs 58: 553–578.
2. Berdoukas V, Bentlev P, Frost H, Schnebli HP (1993) Toxicity of oral iron chelator L1. Lancet 341: 1088–1093.
3. Bosque MA, Domingo JL, Corbella J (1995) Assessment of the developmental toxicity of desferrioxamine in mice. Arch Toxicol 69: 871–872.
4. Clarke ET, Martell AE (1992) Stabilities of 1,2-dimethyl-3-hydroxypyrid-4-one chelates of divalent and trivalent metal ions. Inorg Chim Acta 19: 57–63.
5. Dill K, McGown EL (1994) The biochemistry of arsenic, bismuth and antimony. In: S Patai (ed), The Chemistry of Arsenic, Antimony and Bismuth Compounds. New York, NY: John Wiley and Sons, pp. 695–713.
6. Flora SJS, Bhattacharyan R, Vijayaraghavan R (1995) Combined therapeutic potential of meso-dimercaptosuccinic acid and calcium edentate on the mobilization and distribution of lead in experimental lead intoxication in rats. Fundam Appl Toxicol 25: 233–240.
7. Franchini M, Gandini G, de Gironcoli M, Vassanelli A, Borgna-Pignatti C, Aprili G (2000) Safety and efficacy of subcutaneous bolus injection of desferroxamine in adult patients with iron overload. Blood 5: 2776–2779.
8. Gomez W, Esparza JL, Domingo JL, Singha PK, Jones MM (1988) Comparative aluminium mobilizing action of desferrioxamine and four 3-hydroxypyrid-4-ones in aluminium-loaded rats. Toxicology 130: 175–181.
9. Gomez W, Esparza JL, Domingo JL, Singha PK, Corbella J, Jones MM (1988) Aluminum distribution and excretion: a comparative study of a number of chelating agent in rats. Pharmacol Toxicol 82: 295–300.
10. Hershko C, Link G, Konun AM, Ioav CZ (2005) Objectives and mechanism of iron chelation therapy. Ann N Y Acad Sci 1054: 124–135.
11. Hershko C (2002) Role of iron chelation therapy in thalassemia major. Turk J Haematol 19: 121–126.
12. Kontoghiorghes GJ (1995) New concepts of iron and aluminium chelation therapy with orally L1 (deferiprone) and other chelators. Analyst 120: 845–851.
13. Kontoghiorghes GJ, Sheppard L (1987) Simple synthesis of the potent chelators l-alkyl-3-hydroxy-2-mehylpyrid-4-ones. Inorg Chim Acta 136: 111–112.
14. Kontoghiorghes GJ, Aldouri MA, Sheppard L, Hoffbrand AV (1987) 1, 2 Dimethyl-3-hydroxyprid-4-one an orally activechelator for treatment of iron overload. Lancet 1: 1294–1295.
15. Kostial K, Piasek M, Blanusa M, Schonwald N, Jones MM, Singh PK (1996) Combined treatment with a new biscarbodithioate C9G2DTC and BGDTC for mobilizing cadmium deposits in rats. J Appl Toxicol 16: 157–158.
16. Kostial K, Restek-samarzija K, Blanusa B, Piasek M jones, MM, Singh, PK (1997) Combined oral treatment with racemic and meso-2,3 dimercaptosuccinic acid for removal of mercury in rats. Pharmacol Toxicol 81: 242–244.
17. Slikkerveer A, de Wolff FA (1989) Pharmacokinetics and toxicity of bismuth compounds. Med Toxicol Adverse Drug Exp 4: 303–323.